Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today’s medicine can only offer symptom management at best. Their mission is to translate ground-breaking science into medicines that transform patients’ lives.

Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. Their rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations.